Key result
Intracoronary Egr-1 DNAzyme improves postreperfusion LVEF by ~12 percentage points in preclinical model.
Why the study?
Does intracoronary delivery of DNAzyme targeting Egr-1 improve heart function and reduce myocardial infarction in a pig model of myocardial ischemia-reperfusion injury?
Does intracoronary delivery of DNAzyme targeting Egr-1 improve heart function and reduce myocardial infarction in a pig model of myocardial ischemia-reperfusion injury?
Answers are grounded in this paper and cite their sources.
Egr-1 silencing via intracoronary DNAzyme at reperfusion reduces myocardial inflammation and apoptosis, improving cardiac function in a preclinical model of myocardial infarction.
BACKGROUND: Egr-1 is implicated in the pathogenesis of myocardial ischemia-reperfusion injury. The aim of this study was to ascertain the effectiveness of intracoronary delivery of DNAzyme targeting the transcription factor Egr-1 at reperfusion following experimental myocardial ischemia. METHODS AND RESULTS: Functional DNAzyme targeting Egr-1 or a size-matched scrambled control were delivered via the intracoronary route immediately on reperfusion after 60 minutes' balloon occlusion of the left anterior descending coronary artery in a pig model of myocardial I/R injury (n=7 per treatment group). Heart function and extent of myocardial infarction were determined following intervention by echocardiography and cardiac magnetic resonance imaging, respectively. Hearts were removed and examined for molecular and histological markers of inflammation and apoptosis. Administration of functional DNAzyme led to an overall decrease in the expression of inflammatory markers including intracellular adhesion molecule-1, tissue factor, and complement 3, with associated decreases in the extent of neutrophil infiltration, oxidative damage, and subsequent apoptosis within the infarct border zone. Functional significance was indicated by an increase in salvaged left ventricular myocardium (P=0.012), ejection fraction (P=0.002), and fractional area change (P=0.039) in the functional DNAzyme-treated group compared with the control. CONCLUSIONS: Egr-1 silencing through intracoronary delivery of a targeting DNAzyme at the time of reperfusion following acute myocardial ischemia decreases myocardial inflammation and apoptosis leading to improved cardiac function.
No takes yet. Share an insight, caveat, or question.
Rayner et al. (2013) studied Myocardial ischemia-reperfusion injury / Myocardial infarction (n=21). Functional DNAzyme targeting Egr-1 (DZF) vs. Size-matched scrambled control DNAzyme (DZF Scr) was evaluated on Left ventricular ejection fraction (LV EF) at 48 hours postreperfusion (p=0.002). Intracoronary Egr-1-targeting DNAzyme increased left ventricular ejection fraction and improved myocardial salvage by 84% compared to control in pigs.
Synapse has enriched 10 related papers. Consider them for comparative context: